高艳锋教授团队在肿瘤免疫治疗多肽药物方面的研究成果“Design of a Novel Chimeric Peptide via Dual Blockade of CD47/SIRPα and PD-1/PD-L1 for Cancer Immunotherapy”。

目前国内免疫药物主要有PD-1单抗和PD-L1单抗两大类。大家可能觉得，这两种药物其实是针对同一免疫通路的两个端点，机制上似乎是一致的。其实不然，两者之间存在着一定的区别，无论是在药物设计、作用机制到临床疗效，甚至耐药处理上都有不同之处。今天就全面给 ...

Studying patients with PD-1 or PD-L1 deficiency may help inform new approaches to fine-tuning immunotherapies to maximise ...

PD-1 blockade therapy is a checkpoint inhibitor that blocks this signaling process, unleashing the full fury of T cells. Still, only 20% to 40% of patients receive clear benefits from this kind of ...

A research team from the Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences has revealed ...

Compared with PD-1 inhibition alone, dual checkpoint blockade strongly improved the tumor microenvironment by increasing the ...

Dana-Farber Cancer Institute authors: Giuseppe Tarantino, PhD, David Liu, MD, MPH ...